First immunotoxin therapy for many common solid tumors enters phase I clinical trial.
Skolnick
A A
AA
D036002:ADP Ribose Transferases; D001427:Bacterial Toxins / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy; D017321:Clinical Trials, Phase I as Topic; D003110:Colonic Neoplasms / Q000628:therapy; D005098:Exotoxins / Q000627:therapeutic use*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D009369:Neoplasms / Q000628:therapy*; D011550:Pseudomonas aeruginosa; D011994:Recombinant Proteins / Q000627:therapeutic use; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D001427:Bacterial Toxins; D005098:Exotoxins; D000922:Immunotoxins; D011994:Recombinant Proteins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A